Treatment of painful hypertrophic osteoarthropathy associated with non-small cell lung cancer with octreotide: a case report and review of the literature

Abstract

Hypertrophic osteoarthropathy (HOA) is a syndrome most commonly associated with non-small cell lung cancer and consists of periostitis, digital clubbing and painful polyarthropathy. Its symptoms may be disabling and are reportedly difficult to manage effectively with conventional analgesia. We present a case of a lung cancer patient with opioid resistant painful HOA in whom analgesia was achieved with octreotide.

Secondary Hypertrophic Osteoarthropathy or Pierre-Marie Syndrome Bamberger: Clinical Case and Literature Review

“…Definitive treatment aims to remedy the underlying cause, including surgical resection, definitive chemotherapy or radiofrequency ablation for a primary malignancy of the lung [17] [18]. Symptomatic treatment (NSAIDs, octreotide, bisphosphonates, and specific growth factor inhibitors) is used in patients in whom the primary aetiology cannot be treated [19].…”

Primary idiopathic hypertrophic osteoarthropathy in a child: characteristics of the disease with a case report

“…Ретиноиды уменьшают количество матричной РНК проколлагена в фибробластах, что снижает их способ-ность синтезировать новые молекулы коллагена и приво-дит к уменьшению выраженности пахидермии, себореи, акне, фолликулита [38]. Отдельные сообщения указыва-ют, что октреотид также способен уменьшать степень вы-раженности костного болевого синдрома [39].…”